CSS
NVO

Cubist Systematic Strategies’s Novo Nordisk NVO Stock Holding History

Cubist Systematic Strategies’s Portfolio NVO Stock Details NVO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q1 		– Sell
-100
Closed -$8.6K – 3317
2024
Q4 		$8.6K Buy
+100
New +$10.8K ﹤0.01% 2866
2023
Q4 		– Sell
-4,200
Closed -$382K – 3933
2023
Q3 		$382K Hold
4,200
– – ﹤0.01% 2468
2023
Q2 		$340K Buy
+4,200
New +$343K ﹤0.01% 2575
2022
Q4 		– Sell
-9,200
Closed -$458K – 4492
2022
Q3 		$458K Buy
+9,200
New +$493K ﹤0.01% 3232

Other funds holding NVO

Capital International Investors
Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return
Loomis, Sayles & Company
Loomis, Sayles & Company Boston, Massachusetts $74.3B AUM 24.01% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Fisher Asset Management
Fisher Asset Management Camas, Washington $295B AUM 31.6% 1-Year Est. Return
F
Folketrygdfondet Oslo Norway, Norway $5.64B AUM 47.16% 1-Year Est. Return
Fayez Sarofim & Co
Fayez Sarofim & Co Houston, Texas $39.1B AUM 15.14% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Cubist Systematic Strategies's NVO Position: Q2 2024 in Review

Cubist Systematic Strategies sold out of Novo Nordisk (NVO) in Q2 2024, closing a stake of 216,596 shares — an estimated $27.8M sold.

Cubist Systematic Strategies first reported a position in NVO in Q2 2014 and held it in 37 quarters. The position peaked at $27.8M in Q1 2024. 1,861 funds tracked by Wall St. Rank hold NVO as of Q2 2024.

  • Cubist Systematic Strategies reported no remaining Novo Nordisk position as of Q2 2024 after selling out during the quarter.
  • Cubist Systematic Strategies sold 216,596 Novo Nordisk shares in Q2 2024, an estimated $27.8M.
  • Cubist Systematic Strategies first reported a position in Novo Nordisk in Q2 2014 and held it in 37 quarters.
  • Cubist Systematic Strategies's Novo Nordisk position peaked at $27.8M in Q1 2024.
  • 1,861 funds tracked by Wall St. Rank held Novo Nordisk as of Q2 2024.

Based on Cubist Systematic Strategies's 13F filing for Q2 2024, filed 14 Aug 2024.